Literature DB >> 11817990

Onychomycosis: health-related quality of life considerations.

James W Shaw1, Vijay N Joish, Stephen Joel Coons.   

Abstract

The symptoms of onychomycosis and their impact on personal appearance are important determinants of patients' perceptions of their own health. The effect of onychomycosis is greater on psychosocial than physical functioning and is directly related to the extent of nail involvement. This review identified a number of disease-targeted questionnaires that have been developed to assess the impact of onychomycosis and its treatment on health-related quality of life (HR-QOL). The instruments differ considerably in the extent to which they have been psychometrically tested. Most have been shown to provide both valid and reliable measurement of HR-QOL in patients with onychomycosis of the toes. However, not all have been tested in patients with fingernail disease. The generic and disease-targeted scales of most of the available questionnaires exhibit poor variability, which may limit their responsiveness to clinically important change. Only one instrument, the Onychomycosis Disease-Specific Questionnaire, has been incorporated into a clinical trial. Thus, information relating to the impact of onychomycosis treatment on HR-QOL is limited. Future efforts should focus on the systematic evaluation of existing questionnaires in all populations for which they were developed. In addition, it is important that disease-targeted measures be included in future clinical trials so that a better understanding of the impact of onychomycosis treatment on patient HR-QOL may be gained.

Entities:  

Mesh:

Year:  2002        PMID: 11817990     DOI: 10.2165/00019053-200220010-00003

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  36 in total

1.  Quality of life issues for patients with fungal nail infections.

Authors:  L Drake
Journal:  AIDS Patient Care       Date:  1995-12

2.  Responsiveness in quality-of-life assessment: nomenclature, determinants, and clinical applications.

Authors:  R S Epstein
Journal:  Med Care       Date:  2000-09       Impact factor: 2.983

Review 3.  Generic and disease-specific measures in assessing health status and quality of life.

Authors:  D L Patrick; R A Deyo
Journal:  Med Care       Date:  1989-03       Impact factor: 2.983

Review 4.  Clinical and economic factors in the treatment of onychomycosis.

Authors:  T R Einarson; A K Gupta; N H Shear; S Arikian
Journal:  Pharmacoeconomics       Date:  1996-04       Impact factor: 4.981

5.  Effect of onychomycosis on quality of life.

Authors:  L A Drake; R K Scher; E B Smith; G A Faich; S L Smith; J J Hong; M J Stiller
Journal:  J Am Acad Dermatol       Date:  1998-05       Impact factor: 11.527

6.  Onychomycosis is more than a cosmetic problem.

Authors:  R K Scher
Journal:  Br J Dermatol       Date:  1994-04       Impact factor: 9.302

7.  Physical attractiveness, happiness, neuroticism, and self-esteem.

Authors:  E W Mathes; A Kahn
Journal:  J Psychol       Date:  1975-05

8.  A multinational pharmacoeconomic analysis of oral therapies for onychomycosis. The Onychomycosis Study Group.

Authors:  S R Arikian; T R Einarson; G Kobelt-Nguyen; F Schubert
Journal:  Br J Dermatol       Date:  1994-04       Impact factor: 9.302

9.  Auranofin therapy and quality of life in patients with rheumatoid arthritis. Results of a multicenter trial.

Authors:  C Bombardier; J Ware; I J Russell; M Larson; A Chalmers; J L Read
Journal:  Am J Med       Date:  1986-10       Impact factor: 4.965

Review 10.  Measuring health-related quality of life.

Authors:  G H Guyatt; D H Feeny; D L Patrick
Journal:  Ann Intern Med       Date:  1993-04-15       Impact factor: 25.391

View more
  10 in total

Review 1.  Oral antifungal medication for toenail onychomycosis.

Authors:  Sanne Kreijkamp-Kaspers; Kate Hawke; Linda Guo; George Kerin; Sally Em Bell-Syer; Parker Magin; Sophie V Bell-Syer; Mieke L van Driel
Journal:  Cochrane Database Syst Rev       Date:  2017-07-14

Review 2.  Patient-Reported Outcomes in Onychomycosis: A Review of Psychometrically Evaluated Instruments in Assessing Treatment Effectiveness.

Authors:  Jenny Wang; Lauren E Wiznia; Evan A Rieder
Journal:  Skin Appendage Disord       Date:  2017-04-21

Review 3.  Fungal toenail infections.

Authors:  Jill Ferrari
Journal:  BMJ Clin Evid       Date:  2011-08-16

4.  2-(benzylideneamino)phenol: a promising hydroxyaldimine with potent activity against dermatophytoses.

Authors:  Alan Kiill Gasparto; Ludmila Matos Baltazar; Ludmila Ferreira Gouveia; Cleiton Moreira da Silva; Ricardo Martins Duarte Byrro; Milene Alvarenga Rachid; Armando da Silva Cunha Júnior; Maria Aparecida de Resende-Stoianoff; Angelo de Fátima; Daniel Assis Santos
Journal:  Mycopathologia       Date:  2014-12-17       Impact factor: 2.574

5.  Treatment of onychomycosis with efinaconazole 10% topical solution and quality of life.

Authors:  Antonella Tosti; Bom E Elewski
Journal:  J Clin Aesthet Dermatol       Date:  2014-11

Review 6.  Fungal toenail infections.

Authors:  Jill Ferrari
Journal:  BMJ Clin Evid       Date:  2008-12-15

Review 7.  Fungal toenail infections.

Authors:  Jill Ferrari
Journal:  BMJ Clin Evid       Date:  2014-03-13

Review 8.  The Impact of Onychomycosis on Quality of Life: A Systematic Review of the Available Literature.

Authors:  Aditya K Gupta; Rachel R Mays
Journal:  Skin Appendage Disord       Date:  2018-02-13

9.  Enhanced Enzymatic Activity of Yeast-like Fungi Responsible for Onychomycosis in Renal Transplant Recipients.

Authors:  Jolanta Weglowska; Adam Reich; Bronisława Walów; Jacek C Szepietowski
Journal:  Int J Biomed Sci       Date:  2006-02

10.  Psychosocial perception of adults with onychomycosis: a blinded, controlled comparison of 1,017 adult Hong Kong residents with or without onychomycosis.

Authors:  Henry Hl Chan; Emma T Wong; Chi Keung Yeung
Journal:  Biopsychosoc Med       Date:  2014-07-15
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.